Table 1 Comparisons of baseline characteristics of HCC patients who received IATs.
Characteristic | IAT alone group | IAT combination group | p-value | HAIC | TACE | p-value |
---|---|---|---|---|---|---|
(n = 1103) | (n = 1856) | (n = 798) | (n = 1058) | |||
Age (years), n (%) | ||||||
≤65 | 947 (85.86) | 1517 (81.73) | 0.004 | 691 (86.59) | 826 (78.07) | <0.001 |
>65 | 156 (14.14) | 339 (18.27) | 107 (13.41) | 232 (21.93) | ||
Gender, n (%) | ||||||
Female | 127 (11.51) | 241 (12.98) | 0.265 | 90 (11.28) | 151 (14.27) | 0.067 |
Male | 976 (88.49) | 1615 (87.02) | 708 (88.72) | 907 (85.73) | ||
ECOG, n (%) | ||||||
0 | 1026 (93.02) | 1724 (92.89) | 0.952 | 714 (89.47) | 1010 (95.46) | <0.001 |
1 | 77 (6.98) | 132 (7.11) | 84 (10.53) | 48 (4.54) | ||
Comorbidity, n (%) | ||||||
Absence | 964 (87.40) | 1650 (88.90) | 0.241 | 691 (86.59) | 959 (90.64) | 0.007 |
Presence | 139 (12.60) | 206 (11.10) | 107 (13.41) | 99 (9.36) | ||
Aetiology, n (%) | ||||||
Absence | 81 (7.34) | 128 (6.90) | 0.892 | 61 (7.64) | 67 (6.33) | 0.513 |
HBV | 1009 (91.48) | 1705 (91.86) | 728 (91.23) | 977 (92.34) | ||
HCV | 13 (1.18) | 23 (1.24) | 9 (1.13) | 14 (1.32) | ||
Cirrhosis, n (%) | ||||||
Absence | 65 (5.89) | 68 (3.66) | 0.006 | 68 (8.52) | 0 (0.00) | <0.001 |
Presence | 1038 (94.11) | 1788 (96.34) | 730 (91.48) | 1058 (100.00) | ||
Ascites, n (%) | ||||||
Absence | 929 (84.22) | 1590 (85.67) | 0.311 | 679 (85.09) | 911 (86.11) | 0.58 |
Presence | 174 (15.78) | 266 (14.33) | 119 (14.91) | 147 (13.89) | ||
Tumour diameter, n (%) | ||||||
≤5 | 75 (6.80) | 249 (13.42) | <0.001 | 48 (6.02) | 201 (19.00) | <0.001 |
5–10 | 367 (33.27) | 698 (37.61) | 252 (31.58) | 446 (42.16) | ||
>10 | 661 (59.93) | 909 (48.98) | 498 (62.41) | 411 (38.85) | ||
Tumour number, n (%) | ||||||
1–3 | 447 (40.53) | 971 (52.32) | <0.001 | 370 (46.37) | 601 (56.81) | <0.001 |
>3 | 656 (59.47) | 885 (47.68) | 428 (53.63) | 457 (43.19) | ||
Vascular invasion, n (%) | ||||||
Absence | 446 (40.44) | 1042 (56.14) | <0.001 | 348 (43.61) | 694 (65.60) | <0.001 |
Presence | 657 (59.56) | 814 (43.86) | 450 (56.39) | 364 (34.40) | ||
Metastasis, n (%) | ||||||
Absence | 744 (67.45) | 1355 (73.01) | 0.001 | 523 (65.54) | 832 (78.64) | <0.001 |
Presence | 359 (32.55) | 501 (26.99) | 275 (34.46) | 226 (21.36) | ||
BCLC, n (%) | ||||||
A | 129 (11.70) | 392 (21.12) | <0.001 | 108 (13.53) | 284 (26.84) | <0.001 |
B | 196 (17.77) | 435 (23.44) | 134 (16.79) | 301 (28.45) | ||
C | 778 (70.53) | 1029 (55.44) | 556 (69.67) | 473 (44.71) | ||
ALB(g/L), n (%) | ||||||
≤35 | 285 (25.84) | 633 (34.11) | <0.001 | 253 (31.70) | 380 (35.92) | 0.065 |
>35 | 818 (74.16) | 1223 (65.89) | 545 (68.30) | 678 (64.08) | ||
ALT (g/L), n (%) | ||||||
≤40 | 464 (42.07) | 823 (44.34) | 0.242 | 338 (42.36) | 485 (45.84) | 0.147 |
>40 | 639 (57.93) | 1033 (55.66) | 460 (57.64) | 573 (54.16) | ||
AST (g/L), n (%) | ||||||
≤40 | 250 (22.67) | 502 (27.05) | 0.009 | 164 (20.55) | 338 (31.95) | <0.001 |
>40 | 853 (77.33) | 1354 (72.95) | 634 (79.45) | 720 (68.05) | ||
TBIL (ng/ml), n (%) | ||||||
≤17.1 | 660 (59.84) | 1092 (58.84) | 0.619 | 477 (59.77) | 615 (58.13) | 0.506 |
>17.1 | 443 (40.16) | 764 (41.16) | 321 (40.23) | 443 (41.87) | ||
ALBI grade, n (%) | ||||||
1 | 630 (57.12) | 928 (50.00) | <0.001 | 417 (52.26) | 511 (48.30) | 0.026 |
2 | 468 (42.43) | 897 (48.33) | 374 (46.87) | 523 (49.43) | ||
3 | 5 (0.45) | 31 (1.67) | 7 (0.88) | 24 (2.27) | ||
PT (ng/ml), n (%) | ||||||
≤13 | 196 (17.77) | 287 (15.46) | 0.112 | 88 (11.03) | 199 (18.81) | <0.001 |
>13 | 907 (82.23) | 1569 (84.54) | 710 (88.97) | 859 (81.19) | ||
INR (ng/ml), n (%) | ||||||
≤1 | 399 (36.17) | 687 (37.02) | 0.675 | 219 (27.44) | 468 (44.23) | <0.001 |
>1 | 704 (63.83) | 1169 (62.98) | 579 (72.56) | 590 (55.77) | ||
PLT (ng/ml), n (%) | ||||||
≤100 | 114 (10.34) | 490 (26.40) | <0.001 | 46 (5.76) | 444 (41.97) | <0.001 |
>100 | 989 (89.66) | 1366 (73.60) | 752 (94.24) | 614 (58.03) | ||
CRP (ng/ml), n (%) | ||||||
≤30 | 809 (73.35) | 1537 (82.81) | <0.001 | 605 (75.81) | 932 (88.09) | <0.001 |
>30 | 294 (26.65) | 319 (17.19) | 193 (24.19) | 126 (11.91) | ||
Cre (ng/ml), n (%) | ||||||
≤65 | 250 (22.67) | 279 (15.03) | <0.001 | 206 (25.81) | 73 (6.90) | <0.001 |
>65 | 853 (77.33) | 1577 (84.97) | 592 (74.19) | 985 (93.10) | ||
Neu (ng/ml), n (%) | ||||||
≤5.5 | 781 (70.81) | 1452 (78.23) | <0.001 | 607 (76.07) | 845 (79.87) | 0.056 |
>5.5 | 322 (29.19) | 404 (21.77) | 191 (23.93) | 213 (20.13) | ||
Ly (ng/ml), n (%) | ||||||
≤1.5 | 592 (53.67) | 1030 (55.50) | 0.355 | 438 (54.89) | 592 (55.95) | 0.681 |
>1.5 | 511 (46.33) | 826 (44.50) | 360 (45.11) | 466 (44.05) | ||
NLR, n (%) | ||||||
≤4 | 531 (48.14) | 1064 (57.33) | <0.001 | 405 (50.75) | 659 (62.29) | <0.001 |
>4 | 572 (51.86) | 792 (42.67) | 393 (49.25) | 399 (37.71) | ||
PLR, n (%) | ||||||
≤112 | 994 (90.12) | 1776 (95.69) | <0.001 | 722 (90.48) | 1054 (99.62) | <0.001 |
>112 | 109 (9.88) | 80 (4.31) | 76 (9.52) | 4 (0.38) | ||
SII, n (%) | ||||||
≤3000 | 998 (90.48) | 1777 (95.74) | <0.001 | 723 (90.60) | 1054 (99.62) | <0.001 |
>3000 | 105 (9.52) | 79 (4.26) | 75 (9.40) | 4 (0.38) | ||
AFP (ng/ml), n (%) | ||||||
≤400 | 134 (12.15) | 227 (12.23) | 0.994 | 134 (16.79) | 93 (8.79) | <0.001 |
>400 | 969 (87.85) | 1629 (87.77) | 664 (83.21) | 965 (91.21) | ||
PIVKA (ng/ml), n (%) | ||||||
≤400 | 199 (18.04) | 437 (23.55) | 0.001 | 142 (17.79) | 295 (27.88) | <0.001 |
>400 | 904 (81.96) | 1419 (76.45) | 656 (82.21) | 763 (72.12) | ||
Treatment modality, n (%) | ||||||
HAIC | 915 (82.96) | 798 (43.00) | <0.001 | 798 (100.00) | 0 (0.00) | <0.001 |
TACE | 188 (17.04) | 1058 (57.00) | 0 (0.00) | 1058 (100.00) | ||
Local therapy, n (%) | ||||||
Absence | 833 (75.52) | 1462 (78.77) | 0.045 | 651 (81.58) | 811 (76.65) | 0.012 |
Presence | 270 (24.48) | 394 (21.23) | 147 (18.42) | 247 (23.35) |